期刊文献+

Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma:An in vitro study 被引量:18

Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma:An in vitro study
下载PDF
导出
摘要 AIM: To construct an eukaryotic superantigen gene expression vector containing the recombinant gene of SEA and CD80 molecule transmembrane region (CD80TM), and to expresss taphylococcus enterotoxin A (SEA) on the membrane of hepatocellular carcinoma (HCC) cell to form a superantigen gene modified tumor vaccine for HCC. METHODS: SEA and linker-CD80TM gene were amplified through PCR from plasmid containing cDNA of SEA and CD80.Gene fragments were then subcloned into the multiple cloning sites of retroviral vector pLXSN. Recombinant plasmid was transferred into HepG2 cells mediated with lipofectamine,positive clones were selected in culture medium containing G418. RT-PCR and indirect immunofluorescence studies confirmed that SEA was expressed specifically on HCC cell membrane. INFT-ELISPOT study demonstrated that SEA protein was expressed on the membrane of HCC cells.Cytotoxicity of HepG2-SEA primed CTLs (SEA-T) was analyzed by^51Cr release assay. T cells cultured with rhIL-2 (IL-2-T) were used as control. RESULTS: Restriction digestion and sequence analyses confirmed the correctness of length, position and orientation of inserted fusion genes. SEA was expressed on the surface of HepG2 cells, HepG2-SEA had strong stimulating effect on production of HepG2 specific CTL (P<0.001). SEA-T had enhanced cytotoxicity to HepG2 cells (P<0.05). CONCLUSION: Tumor cell membrane expressed superarfdgen can be used to reinforce the immune effect of tumor cell vaccine for HCC, which provides a new method of the enhanced active immunotherapy for HCC. AIM:To construct an eukaryotic superantigen gene expression vector containing the recombinant gene of SEA and CD80 molecule transmembrane region (CD80TM),and to express staphylococcus enterotoxin A (SEA) on the membrane of hepatocellular carcinoma (HCC) cell to form a superantigen gene modified tumor vaccine for HCC. METHODS:SEA and linker-CD80TM gene were amplified through PCR from plasmid containing cDNA of SEA and CD80. Gene fragments were then subcloned into the multiple cloning sites of retroviral vector pLXSN.Recombinant plasmid was transferred into HepG2 cells mediated with lipofectamine, positive clones were selected in culture medium containing G418.RT-PCR and indirect immunofluorescence studies confirmed that SEA was expressed specifically on HCC cell membrane.INFγ-ELISPOT study demonstrated that SEA protein was expressed on the membrane of HCC cells. Cytotoxicity of HepG2-SEA primed CTLs (SEA-T) was analyzed by ^(51)Cr release assay.T cells cultured with rhIL-2 (IL-2-T) were used as control. RESULTS:Restriction digestion and sequence analyses confirmed the correctness of length,position and orientation of inserted fusion genes.SEA was expressed on the surface of HepG2 cells,HepG2-SEA had strong stimulating effect on production of HepG2 specific CTL (P<0.001).SEA-T had enhanced cytotoxicity to HepG2 cells (P<0.05). CONCLUSION:Tumor cell membrane expressed superantigen can be used to reinforce the immune effect of tumor cell vaccine for HCC,which provides a new method of the enhanced active immunotherapy for HCC.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2004年第1期53-57,共5页 世界胃肠病学杂志(英文版)
基金 Supported by National Natural Science Foundation of China,No.30271474 and No.39770827
  • 相关文献

参考文献34

  • 1Teshima T, Mach N, Hill GR, Pan L, Gillessen S, Dranoff G,Ferrara JL. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation.Cancer Res 2001; 61:162-171.
  • 2Nelson WG, Simons JW, Mikhak B, Chang JF, DeMarzo AM,Carducci M.A, Kim M, Weber CE, Baccala AA. Goeman MA, Clift SM, Ando DG, Levitsky HI, Cohen LK, Sanda MG, Mulligan RC,Partin AW, Carter HB, Piantadosi S, Marshall FF. Cancer cell sengineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies. Cancer Chemother Pharmacol 2000; 46(Suppl): S67-S72.
  • 3Antonia SJ, Seigne J, Diaz J, Muro-Cacho C, Extermann M,Farmelo MJ, Friberg M, Alsarraj M, Mahany JJ, Pow-Sang J, Cantor A, Janssen W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemicinterleukin-2 in patients with metastatic renal cell carcinoma. J Uro1 2002; 167:1995-2000.
  • 4Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science 1990; 248:705-711.
  • 5Fraser JD. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. Nature 1989; 339:221-223.
  • 6Kotzin BL, Leung DY, Kappler J, Marrack P. Superantigens and their potential role in human disease. Adv Immunol 1993; 54:99-166.
  • 7Leung DY, Gately M, Trumble A, Ferguson-Damell B, Schlievert PM, Picker LJ. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyteassociated antigen, via stimulation of interleukin 12 production.J Exp Med 1995; 181:747-753.
  • 8Sriskandan S, Evans TJ, Cohen J. Bacterial superantigen-induced human lymphocyte responses are nitric oxide dependenand mediated by IL-12 and IFN-gamma. J Immunol 1996; 156:2430-2435.
  • 9Lando PA, Hedlund G, Dohlsten M, Kalland T. Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.Cancer Immunol Immunother 1991; 33 231-237.
  • 10Ochi A, Migita K, Xu J, Siminovitch K. In vivo tumor immunotherapy by a bacterial superantigen. J Immunol 1993; 151:3180-3186.

同被引文献77

引证文献18

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部